BE657005A - - Google Patents

Info

Publication number
BE657005A
BE657005A BE657005A BE657005A BE657005A BE 657005 A BE657005 A BE 657005A BE 657005 A BE657005 A BE 657005A BE 657005 A BE657005 A BE 657005A BE 657005 A BE657005 A BE 657005A
Authority
BE
Belgium
Prior art keywords
sorbitol
vitamins
medicaments according
antibiotic
intestinal
Prior art date
Application number
BE657005A
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE657005A publication Critical patent/BE657005A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

  

   <Desc/Clms Page number 1> 
 



  "Nouvelles associations médicamenteuses destinées à la reconsti- tution de la flore intestinale" 
On sait l'importance que revêt après un traitement aux antibiotiques le réensemencement de la flore intestinale, toujours plus ou moins profondément dégradée sous l'influença de ces médicaments. 



   On utilise généralement à cet effet des cultures déshy- 

 <Desc/Clms Page number 2> 

 drames ou lyophilisées de différents bacille lont un des rôles est; de permettre au milieu intestinal de secréser les vitamines - en particulier du groupe B - indispensable   au '    notionnement     équilibré   de l'organisme, 
Les nouveaux médicaments faisant   l'o@  et de la pré-   tante   demande de Brevet Spécial de Médicament avnt caractérisés par le fait qu'ils comportent à côté des   cultur   vivantes con-   venablement   déshydratées des différents bacille que l'on dési- reréintroduire dans le milieu intestinal, une   c@@@aine   quantité de Sorbitol. 



   La présence de celui-ci exerce une   infl j  nce considé- rable en permettant une assimilation beaucoup plu rapide, dès leur formation, des vitamines que les bacillos   nc'-.   tellement in-   trc@uits   sécrètent,assurant par cela même un taux t'assimilation beaucoup plus important. 



   .   Il   est remarquable que l'action légèrement   @actéric-   statique du Sorbitol n'exerce aucune influence nocive sur le   développement   dos cultures une fois réintroduites dans lè milieu favorable. 



   Les bacilles susceptibles d'être utilisés sans inoon- vénients en présence' du Sorbitol doivent être de préférence vi- vants et originaires de souches antibiorésistantes. Parmi ceux qui sont susceptibles   d'être   utilisés avec les meilleurs résul- tats   on   peut citer :le Bacillus Subtilis, les Saccharomyces,   bacillus lactis.bacillus aoidophilus,les streptocoques tels que les bacilles lactiques tels que sureptococcus lactis, streptocoo-   cas thermophilus,ainsi que   bacillum   bulgaricus,  escherichia   coli 
Les quantités de germes vivants pouvant être utilisés varient suivant les espèces utilisées de   1   million à   100   mil- liards ou même davantage, par unité de prise.

   Il est toutefois   à   noter que les quantités correspondant à l'activité optima 
 EMI2.1 
 outé 8 motl sont;. généralement inférieures à. celles utilisées lors de l'emploi prouvât san.sSorbitol, du fait du meilleur taux d'assimilation des vita- ux xzacs,- ;u groupe B sécrétées par les bactéries. 

 <Desc/Clms Page number 3> 

 



     :La   quantité de Sorbitol nécessaire peut aller jusqu'à 2,5 g par prise. Néanmoins, l'absorption de quantités trop im- portantes est susceptible de provoquer des phénomènes de diar- rhées. L'addition de 0,25 g de Sorbitol par prise évite toujours ce risque et est généralement suffisante pour permettre une as- similation quasi totale des vitamines sécrétées dans le milieu intestinal. 



   Les médicaments selon l'invention peuvent être réali- sés sous toutes les formes pharmaceutiques usuelles, c'est-à-dire gélules, ampoules buvables, préparation lyophylisées, ou même comprimés, en présence des excipients pharmaceutiquement accep- tables. 



   Pour illustrer la présente demande de Brevet Spécial de Médicament, des exemples de réalisation de médicaments selon l'invention sont donnés ci-dessous, sans toutefois que les pré- cisions apportées puissent être interprétées de façon restric- tive quand à la portée générale de l'invention, en particulier en ce qui concerne la nature des germes, le dosage et la poso- logie. 



    EXEMPLE   1 -   Gelules   
Culture lyophylisée de lactobacillus acidophilus antibiorésistant et vivant titrant au moins 1 milliard de germes 
Sorbitol 0,25 g 
Excipient QS pour une gélule 
Posologie :2 à 4 gélules par jour ou davantage,   EXEMPLE   2 -Ampoules buvables 
Bacillus Subtilis antibiorésistant vivant 50 milliards de germas 
Sorbitol 0,50 g 
Excipient QS pour une ampoule buva- ble de   '10   ml   Posologie :   1 à 2 ampoules par jour ou davantage 

 <Desc/Clms Page number 4> 

 
Les médicaments selon   l'invention   peuvent être admi- nistrés de toutes les façons classiques et être adjoints à des alimente, notamment pour un usage pédiatrique.

   Un cas parti-   @   culier de réalisation spécialement intéressant est la prépara- tion dont un exemple est donné ci-dessous où le Sorbitol est adjoint à un   yoehourt   enrichi en germes vivants. 



    EXEMPLE 3 -   Yoghourt spécial 
Yoghourt enrichi en bacillus   bulgarious   antibiorésistant vivant   100   g contenant au moins   100   millions de germes vivants 
Sorbitol   Os?5   g 
Parfum QS 
Posologie !1 à 2 par jour 
Ce mode de réalisation des produits selon l'invention se prête particulièrement à l'aromatisation, notamment avec les extraits naturels de fruits.



   <Desc / Clms Page number 1>
 



  "New drug combinations intended for the reconstitution of the intestinal flora"
We know the importance of the reseeding of the intestinal flora after treatment with antibiotics, which is always more or less deeply degraded under the influence of these drugs.



   Dehydrated cultures are generally used for this purpose.

 <Desc / Clms Page number 2>

 dramas or freeze-dried from different bacillus one of the roles is; to allow the intestinal environment to secrete the vitamins - in particular of the B group - essential for the balanced assessment of the body,
The new drugs forming the subject of the present application for a Special Medicines Patent have been characterized by the fact that they comprise, alongside living cultures, suitably dehydrated, of the various bacilli that one wishes to re-introduce into the intestinal environment, a large amount of Sorbitol.



   The presence of this exerts a considerable influence by allowing a much faster assimilation, as soon as they are formed, of the vitamins than the bacilli nc'-. so many intrusions secrete, thereby assuring a much higher rate of assimilation.



   . It is remarkable that the mildly acteric-static action of Sorbitol exerts no harmful influence on the development of the crops once reintroduced into the favorable environment.



   The bacilli which can be used without inconvenience in the presence of sorbitol should preferably be live and originate from antibiotic resistant strains. Among those which are likely to be used with the best results, mention may be made of: Bacillus Subtilis, Saccharomyces, bacillus lactis, bacillus aoidophilus, streptococci such as lactic bacilli such as sureptococcus lactis, streptococcus thermophilus, as well as as bacillum bulgaricus, escherichia coli
The quantities of live germs which can be used vary according to the species used from 1 million to 100 billion or even more, per unit dose.

   It should be noted, however, that the quantities corresponding to the optimum activity
 EMI2.1
 outé 8 motl are ;. generally less than. those used during employment proved san.sSorbitol, because of the better rate of assimilation of vitamins xzacs, -; u group B secreted by bacteria.

 <Desc / Clms Page number 3>

 



     : The amount of Sorbitol required can be up to 2.5 g per dose. Nevertheless, the absorption of too large quantities is liable to provoke the phenomena of diarrhea. The addition of 0.25 g of Sorbitol per dose always avoids this risk and is generally sufficient to allow almost complete absorption of the vitamins secreted in the intestinal environment.



   The medicaments according to the invention can be produced in all the usual pharmaceutical forms, that is to say capsules, drinkable ampoules, lyophilized preparations, or even tablets, in the presence of pharmaceutically acceptable excipients.



   To illustrate the present Special Medicines Patent application, exemplary embodiments of medicaments according to the invention are given below, without however the details provided being able to be interpreted restrictively as regards the general scope of the invention. The invention, in particular with regard to the nature of the seeds, the dosage and the dosage.



    EXAMPLE 1 - Gelatin capsules
Lyophilized culture of live, antibiotic-resistant lactobacillus acidophilus containing at least 1 billion germs
Sorbitol 0.25 g
Excipient QS for one capsule
Dosage: 2 to 4 capsules per day or more, EXAMPLE 2 - Drinkable ampoules
Antibiotic-resistant Bacillus Subtilis living 50 billion germs
Sorbitol 0.50 g
Excipient QS for a drinkable ampoule of '10 ml Dosage: 1 to 2 ampoules per day or more

 <Desc / Clms Page number 4>

 
The medicaments according to the invention can be administered in all conventional ways and be added to foods, in particular for pediatric use.

   A particularly interesting particular embodiment is the preparation, an example of which is given below, in which Sorbitol is added to a yoghurt enriched with living germs.



    EXAMPLE 3 - Special yoghurt
Yogurt enriched with live antibiotic-resistant bacillus bulgarious 100 g containing at least 100 million live germs
Sorbitol Bone? 5 g
QS fragrance
Dosage! 1 to 2 per day
This embodiment of the products according to the invention is particularly suitable for flavoring, in particular with natural fruit extracts.

 

Claims (1)

RESUME Les médicaments selon l'invention sont caractérisés par le fait qu'ils réunissent dans une même présentation : 1 ) des baciles antibiorésistants et vivants qui se multiplients dans 1'intestin, rétablissant ainsi la flore in- ' testinale productrice de vitamines notamment celles du groupe B 2 ) du Sorbitol qui permet aux vitamines synthétisées par la flore intestinale réensemencées de traverser la barrière intestinale et d'être absorbée dans une proportion très accrue. ABSTRACT The medicaments according to the invention are characterized by the fact that they combine in the same presentation: 1) antibiotic-resistant and living bacteria which multiply in the intestine, thus restoring the intestinal flora which produces vitamins, especially those of group B 2) Sorbitol which allows the vitamins synthesized by the reseeded intestinal flora to cross the intestinal barrier and be absorbed in a very increased proportion. Les médicaments selon l'invention sont caractérisés par une action plus rapide et plus énergique permettant ainsi de -corriger rapidement les troubles carentiels qui se manifestent fréquemment, en particulier à la suite des antibiothérapies. @ The medicaments according to the invention are characterized by a more rapid and more vigorous action thus making it possible to rapidly correct the deficiency disorders which frequently appear, in particular following antibiotic therapy. @
BE657005A 1963-12-13 1964-12-11 BE657005A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR957048A FR3233M (en) 1963-12-13 1963-12-13 New drug combinations intended for the reconstitution of the intestinal flora.

Publications (1)

Publication Number Publication Date
BE657005A true BE657005A (en) 1965-04-01

Family

ID=8818760

Family Applications (1)

Application Number Title Priority Date Filing Date
BE657005A BE657005A (en) 1963-12-13 1964-12-11

Country Status (3)

Country Link
BE (1) BE657005A (en)
FR (1) FR3233M (en)
NL (1) NL6414479A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335107A (en) * 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella

Also Published As

Publication number Publication date
NL6414479A (en) 1965-06-14
FR3233M (en) 1965-04-05

Similar Documents

Publication Publication Date Title
DE60003515T2 (en) BEVERAGES AND FOODS SUITED TO ELIMINATE HELICOBACTER PYLORI
US11160753B2 (en) Transmucosal and transdermal delivery systems
EP2219658B1 (en) Composition based on probiotic bacteria in association with a prebiotic and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of intestinal functionality
Bharath et al. Determination of antibacterial activity of green coffee bean extract on periodontogenic bacteria like Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans: An: in vitro: study
AU2018281141B2 (en) Compositions for management of Helicobacter pylori infections
KR102606636B1 (en) Bacillus velezensis having the effect of preventing or improving for sarcopenia and uses thereof
JPH0138084B2 (en)
US9717751B2 (en) Chitin or derivatives thereof for the prevention and/or treatment of parasitoses
KR20210112342A (en) Strain, composition and method of use
HUP0402024A2 (en) Solid composition containing bacillus-type non-pathogenic bacterial spores
JP3017493B1 (en) Autoimmune disease prevention composition
KR20240152811A (en) Composition for antibacterial and toxicity inhibition against antibiotic-resistant bacteria containing black ginseng extract as an active ingredient
WO1996026732A1 (en) Compositions of lactic acid bacteria and saccharomyces lysates and the therapeutical use thereof
JP7009396B2 (en) MRSA infection protection agent
JPH0217524B2 (en)
BE657005A (en)
KR20220079092A (en) Composition for preventing or treating inflammatory diseases containing new strains
US10695314B2 (en) Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient
RU2472505C2 (en) Therapeutic antimalaria drug based on antimalaria agent and probiotic
US20030109582A1 (en) Methods and compositions for stimulating secretions from paneth cells
KR102847918B1 (en) Anti-inflammatory and anti-bacterial efficacy microorganism and microorganism lysates fermented in media containing Filipendula glaberrima Nakai extracts
CN117224582A (en) Application of lactobacillus plantarum in preparation of product for preventing and/or treating acne
KR20200112804A (en) Pharmaceutical compositions for preventing or treating the acquisition of drug resistant infections comprising a combination of probiotics and prebiotics
KR100319365B1 (en) Medicinal herbs extract for preventing and treating gastric ulcers and the use thereof
RU2149008C1 (en) Method of biopreparation preparing